Neurochemical Changes in the Brain After Fetal Exposure to Fluoxetine, A Serotonin Reuptake Inhibitor (SRI) in Rodents

Author(s): Mona Awad Alonazi, Amina El Gezeery, Afaf El-Ansary, Ramesa Shafi Bhat*

Journal Name: Current Proteomics

Volume 18 , Issue 4 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: In utero exposure to Selective Serotonin Reuptake Inhibitors (SSRI) is considered a risk factor for many neurodevelopmental diseases.

Objective: The aim of this study was to investigate whether prenatal SSRI exposure changes newborn brain chemistry.

Methods: An animal-based study was designed in which the utero SSRI exposed rat pups were compared to one without drug exposure. Neurochemical changes in the infants were assessed after 2 days of birth by estimating the levels of inflammatory cytokines, neurotransmitters, and caspases in the brain exposed to SSRI at the prenatal stage and compared to normal unexposed newborns.

Results: Our results showed significant neurochemical changes in SSRI-exposed newborns. A significant decrease in dopamine, and serotonin levels with a remarkable decrease in noradrenaline in addition to remarkable increase of IFN-γ and caspase-3 levels was observed in the brain tissues of prenatal exposed SSRIs rat pups.

Conclusion: The results suggest that prenatal SSRI treatment may affect brain development of newborn hence should be done warily during the gestation period.

Keywords: Depression, neurotransmitters, pro-inflammatory cytokines, caspases, brain, SSRI.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 4
Year: 2021
Published on: 16 November, 2020
Page: [499 - 504]
Pages: 6
DOI: 10.2174/1570164617999201116154235
Price: $25

Article Metrics

PDF: 160